Skip to main content

New, free course on capturing the value of V1C for healthcare!

Join FDA and DiMe during a 2-day virtual event.

The Patient Matters in the End(point)


April 13, 2023

Discussion Topic

When using digital health technology (DHT) in clinical trials, we need to specify an endpoint. However, does your digital endpoint matter to the patients? Is it based in the context of their life? For regulatory purposes this seems to be an imperative. As such “black box” algorithms, despite their many benefits such as high predictive accuracy, could be a barrier to gaining a label claim.

This paper discusses the difference between a digital biomarker and a digital clinical outcomes assessment. We build on the foundations by focussing on the meaningful aspects of health and suggesting a framework for DHT development based on the DiMe Playbook. We also go one step further in this talk than we did in the paper. Here we start blue sky thinking about how to combine the highly predictive algorithms underlying digital biomarkers with the patient relevant aspects of digital clinical outcomes assessments.

View article

View slides

Watch recording

Join our next project

Help streamline the path to regulatory and commercial success to optimize health outcomes for the greatest number of patients

Join the Integrated Evidence Plans project

Join us
Not today